HC Wainwright Reiterates “Buy” Rating for Aptose Biosciences (NASDAQ:APTO)

HC Wainwright reaffirmed their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Tuesday,Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com started coverage on Aptose Biosciences in a research report on Saturday. They set a “hold” rating for the company.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.19 on Tuesday. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.82. The firm has a 50-day moving average price of $0.32 and a two-hundred day moving average price of $0.51. The firm has a market cap of $11.27 million, a price-to-earnings ratio of -0.06 and a beta of 1.07.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.